[
  {
    "ts": "2026-02-03T01:54:26+00:00",
    "headline": "C4 Therapeutics, Inc. (CCCC): A Bull Case Theory",
    "summary": "We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein […]",
    "url": "https://finance.yahoo.com/news/c4-therapeutics-inc-cccc-bull-015426512.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a0b6e7e9-464d-36f0-b72d-7146e5449f6a",
      "content": {
        "id": "a0b6e7e9-464d-36f0-b72d-7146e5449f6a",
        "contentType": "STORY",
        "title": "C4 Therapeutics, Inc. (CCCC): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein […]",
        "pubDate": "2026-02-03T01:54:26Z",
        "displayTime": "2026-02-03T01:54:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1",
          "originalWidth": 949,
          "originalHeight": 505,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qbitK_60Vc8oncBc9nQEQw--~B/aD01MDU7dz05NDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1.cf.webp",
              "width": 949,
              "height": 505,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wtjhuWw_GHJ65_98O46.rg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/c4-therapeutics-inc-cccc-bull-015426512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/c4-therapeutics-inc-cccc-bull-015426512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CCCC"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]